The research of BIU focuses on neurodegenerative and cardiometabolic as well as lung diseases.

Overview
After signing the contract: (from left to right) Prof. Klaus-Michael Debatin, Prof. Andreas Barner, Theresia Bauer, Prof. Dr. Gerd Schnorrenberg, Prof. Karl-Joachim Ebeling. Photo: University Medical Center Ulm

Boehringer Ingelheim Ulm University BioCenter (BIU)

On October 19, 2011 Prof. Dr. Gerd Schnorrenberg, Senior Vice President of Boehringer Research Germany and Prof. Dr. Karl Joachim Ebeling, President of the University of Ulm, signed the co-operation agreement of the "Public-Private-Partnership-Research Association BIU" in the presence of Theresia Bauer, Minister of Research of the State of Baden-Wuerttemberg, and Prof. Dr. Dr. Andreas Barner, Speaker of the Boehringer Ingelheim management.

The research will focus neurodegenerativecardio metabolic as well as lung diseases. The goals of the newly founded research association are the identification and characterization of new biomarkers, the analysis of misregulated signaling pathways as well as establishing new innovative preclinical and clinical concepts in translational research. The BioCenter is founded according to the structures and criteria of the well-established collaborative research centers of the German Research Foundation (DFG). Boehringer Ingelheim, the State of Baden-Wuerttemberg and the Medical Faculty of the University of Ulm will support the program with 4.5 Million Euros for 8 years with an evaluation after the first three years.
 

Topics

Scientists focussing on cardiometabolic diseases are strongly interested in the extensive interactions between pathologically altered metabolism and cardiovascular diseases.

More

In addition to cardiometabolic and neurodegenerative diseases the lung as a vital organ also forms a focal point in BIU, a unique cooperation in basic research between Ulm University and Boehringer Ingelheim.

More

The multidisciplinary research of the scientists at the Medical Faculty deals with common and rare neurodegenerative changes linked to Morbus Parkinson, Morbus Alzheimer, Chorea Huntington and amyothrophic lateral sklerosis.

More

Steering Committee & Advisory Board - Here you will find the members and structure of our Steering Committee and the Advisory Board.

Call for Proposals: 2nd BIU funding period

Within the Boehringer Ingelheim Ulm University BioCenter (BIU) project proposals for the 2nd funding period can be submitted from now on. The project need to be related to one of the following research fields: CardioMetabolics, Neuroscience, Pulmonology and Immunmodulation. Cooperation projects between working groups of Boehringer Ingelheim and Ulm University are particularly welcome. Please note that due to a reorientation within the Neuroscience field Boehringer Ingelheim does no longer focus on Neurodegenaration, actually the focus of research is on Neuropsychiatry. For more detailled information please see the info sheet and the guidelines (initial and renewal application). Please send your application (including the Excel sheet -application form for funds-) in electronic format (PDF file) as well as a hardcopy by December 4, 2015 (12:00 noon at the latest) to Dr. Lysann Palkowitsch, Medical Faculty, Bereich Forschung, Albert-Einstein-Allee 7, 89081 Ulm, E-Mail: lysann.palkowitsch(at)uni-ulm.de.

The Excel sheet -application form for funds- will be sent on request per E-Mail. Please contact Dr. Lysann Palkowitsch (E-Mail: lysann.palkowitsch(at)uni-ulm.de).

This call for proposal is directed only at staff members of Ulm University and Boehringer Ingelheim Pharma GmbH & Co. KG.

Documents for downloading: 

Please note that those documents are available in German only.